465 related articles for article (PubMed ID: 34785539)
1. Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.
Moding EJ; Nabet BY; Alizadeh AA; Diehn M
Cancer Discov; 2021 Dec; 11(12):2968-2986. PubMed ID: 34785539
[TBL] [Abstract][Full Text] [Related]
2. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
Chen H; Zhou Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
[TBL] [Abstract][Full Text] [Related]
3. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
[TBL] [Abstract][Full Text] [Related]
4. [Research progress on circulating tumor DNA as a biomarker for minimal residual disease in solid tumors].
Chen Y
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Oct; 25(10):1072-1077. PubMed ID: 37905766
[TBL] [Abstract][Full Text] [Related]
5. Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.
Kasi PM; Fehringer G; Taniguchi H; Starling N; Nakamura Y; Kotani D; Powles T; Li BT; Pusztai L; Aushev VN; Kalashnikova E; Sharma S; Malhotra M; Demko ZP; Aleshin A; Rodriguez A; Billings PR; Grothey A; Taieb J; Cunningham D; Yoshino T; Kopetz S
JCO Precis Oncol; 2022 Mar; 6():e2100181. PubMed ID: 35263168
[TBL] [Abstract][Full Text] [Related]
6. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay.
Hashimoto T; Nakamura Y; Oki E; Kobayashi S; Yuda J; Shibuki T; Bando H; Yoshino T
Int J Clin Oncol; 2024 May; 29(5):495-511. PubMed ID: 38551727
[TBL] [Abstract][Full Text] [Related]
7. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
[TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
9. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
[TBL] [Abstract][Full Text] [Related]
10. Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors.
Chen K; Shields MD; Chauhan PS; Ramirez RJ; Harris PK; Reimers MA; Zevallos JP; Davis AA; Pellini B; Chaudhuri AA
Mol Diagn Ther; 2021 Nov; 25(6):757-774. PubMed ID: 34725800
[TBL] [Abstract][Full Text] [Related]
11. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK
Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374
[TBL] [Abstract][Full Text] [Related]
12. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
[TBL] [Abstract][Full Text] [Related]
13. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
[TBL] [Abstract][Full Text] [Related]
14. Liquid biopsies for residual disease and recurrence.
Wan JCM; Mughal TI; Razavi P; Dawson SJ; Moss EL; Govindan R; Tan IB; Yap YS; Robinson WA; Morris CD; Besse B; Bardelli A; Tie J; Kopetz S; Rosenfeld N
Med; 2021 Dec; 2(12):1292-1313. PubMed ID: 35590147
[TBL] [Abstract][Full Text] [Related]
15. ctDNA as promising tool for the assessment of minimal residual disease (MRD) and the need of an adjuvant treatment in gastroesophageal adenocarcinoma.
Piva VM; De Grandis MC; Zuin IS; Angerilli V; Nappo F; Alfieri R; Ahcene Djaballah S; Murgioni S; Bergamo F; Fassan M; Valmasoni M; Lonardi S
Updates Surg; 2023 Feb; 75(2):305-312. PubMed ID: 36272058
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer.
Xia J; Zhang J; Xiong Y; Zhao J; Zhou Y; Jiang T; Zhu J
Expert Rev Mol Diagn; 2023; 23(10):913-924. PubMed ID: 37702546
[TBL] [Abstract][Full Text] [Related]
17. Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA.
Semenkovich NP; Szymanski JJ; Earland N; Chauhan PS; Pellini B; Chaudhuri AA
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349125
[TBL] [Abstract][Full Text] [Related]
18. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
Arisi MF; Dotan E; Fernandez SV
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
[TBL] [Abstract][Full Text] [Related]
19. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal ctDNA profiling in precision oncology and immunο-oncology.
Filis P; Kyrochristos I; Korakaki E; Baltagiannis EG; Thanos D; Roukos DH
Drug Discov Today; 2023 Apr; 28(4):103540. PubMed ID: 36822363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
